

FOR IMMEDIATE RELEASE

CONTACT

Noel Brown - President

T: 866-332-2835

info@hemobioscience.com

**First and only “Ready to Use” quality control product for manual column agglutination testing methods receives FDA clearance**

Research Triangle Park, NC (June 7, 2017) – Hemo bioscience is pleased to announce that MQC-CAT, the first and only “ready to use” quality control product for manual column agglutination technology (CAT) blood bank testing methods, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.

“We are pleased to add MQC-CAT to our portfolio of control products for the transfusion diagnostics market,” said Noel Brown, President of Hemo bioscience. “As the only currently available control product designed specifically for manual column agglutination technology testing methods, MQC-CAT demonstrates our commitment to improving the science in blood banking.”

Validated for use in all manual CAT testing systems currently available in the US, MQC-CAT includes both positive and negative red cells and serums to ensure that ABO and Rh(D) as well as antibody screening and identification reagents are performing as expected.

About

Founded in 2003, Hemo bioscience, Inc. develops, manufactures, and distributes immunohematology reagents and related products for the world wide transfusion diagnostics market. Our customers include industry partners, reference laboratories, buying groups, hospital blood banks, and donor centers.

###